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Modificationsindonorscreeningandtheintroduction oflaboratory testingofdonated blood for
anti-HIV-l and anti-HTLV-I have resulted in a significant reduction in the risks of retroviral
infections from blood transfusion. Presently, theAmerican Red Cross detects an average ofeight
carriers of human immunodeficiency virus, type 1 (HIV-1) per 100,000 otherwise acceptable
blood donors (0.008 percent), compared with an average of 35 per 100,000 (0.035 percent) when
testing for HIV-1 antibodies began in 1985. Surveillance studies in the United States indicate a
small likelihood that HIV-2 carriers will pass current screening procedures and be accepted as
blood donors. Even if an HIV-2-infected person were to be accepted as a blood donor, there is a
42-92 percent likelihood that this person's blood would be detected as infective for HIV-2 and
excluded because of serological cross-reactions that occur in the EIA for HIV-1 antibodies.
During 1989, which was the first year that donated blood was routinely tested for antibodies to
human T-lymphotropic virus, type I (HTLV-I) in the United States, approximately nine in
100,000 donors (0.009 percent) were confirmed positive for antibodies to HTLV-I, and their
donated blood was excluded. Subsequent testing has revealed that a significant number of these
persons whose sera was reactive by the HTLV-I EIA were, in fact, infected by HTLV-II.
Epidemiological studies ofhuman retroviral infections (HIV-1, HIV-2, HTLV-I, and HTLV-II)
continue to provide important data and direction for improving criteria for qualifying blood
donors.
INTRODUCTION
An understanding oftheunique biology ofhuman retroviral infections-specifically,
the prolonged carrier state that has resulted in multiple blood donations and transfu-
sions from persons with undetected infections-has led to major revisions in blood
donor screening and laboratory testing procedures. Beginning with the "Joint State-
ment on Acquired Immune Deficiency Syndrome Related to Transfusion" issued on
January 13, 1983 [1], theAmerican Association ofBlood Banks, American Red Cross,
and the Council of Community Blood Centers have developed a series of revisions to
update standard operating procedures in order to address the special challenges posed
by human retroviral infections.
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Following the discovery in 1984 that a human retrovirus was the cause of the
acquired immunodeficiency syndrome (AIDS) [2], the national blood collection
organizations introduced new operational procedures to protect transfusion recipients
from infection by this agent, currently known as the human immunodeficiency virus,
type1 (HIV-1) [3] . Following the Food and Drug Administration's issuance ofthe first
license to a manufacturer of test kits for HIV-1 antibodies on March 2, 1985, blood
collectors began to test all donated blood in the United States for HIV-1 antibodies [4].
Additional information about donor screening [5], laboratory testing for HIV-1
antibodies [6], and criteria for confirmatory testing [7] are summarized elsewhere.
The identification of HIV-2, a second human retrovirus capable of causing AIDS
[8], has led to efforts to assess the risk of its transmission by blood transfusion and to
plan for additional measures, if appropriate, to protect transfusion recipients in the
United States [9]. Also, based on studies in Japan, the Caribbean, and the United
States, blood services in the United States began testing all donated blood for
antibodies to the human T-lymphotropic virus, type I (HTLV-I) in January 1989
[10-14].
The American Red Cross Blood Services, which collects approximately half of the
blood donated for transfusion in the United States, maintains standardized procedures
oflaboratory testing for infectious diseases in its 54 regional blood centers. The results
of these laboratory tests are reported to Red Cross national headquarters monthly,
where they are reviewed as part of a systemwide surveillance and quality control
program. Also, these test results provide important data on the prevalence of hepatitis
B [15], HIV-1 [16], and HTLV-I [17] infections in the blood donor population.
The following review is based, in part, on these Red Cross data and is intended to
address selected topics that relate to human retroviral infections as these relate to the
safety ofblood transfusions.
HUMAN IMMUNODEFICIENCY VIRUS, TYPE 1 (HIV-1)
Seronegative Window Period
One of the most important unresolved scientific issues related to transfusion-
transmitted HIV-1 infection is the definition of the seronegative window period that
follows HIV-1 infection. Investigators studying early HIV-1 infection in male homosex-
uals, and using in vitro amplification techniques and/or assays for antibodies to
non-structural HIV-1 antigens, have reported the detection of HIV-1 infection as early
as 42 months before standard FDA-licensed enzyme immunoassays (EIAs) for HIV-1
antibodies were reactive [18-22]. These findings suggest that, after infection by
HIV-1, some persons enter a prolonged phase of low viral expression without an
antibody response that is detectable by conventional enzyme immunoassays. Assuming
that these observations are substantiated, the most critical questions that follow are (1)
how often do such prolonged seronegative latency periods occur and (2) are such
HIV-1-infected EIA-seronegative persons capable of transmitting HIV infection via
blood transfusion? As ofJune 30, 1990, the Centers for Disease Control listed only 11
cases of transfusion-associated acquired immunodeficiency syndrome (AIDS) that
werereported during the five years (sincespring 1985) thatblood services in the United
States have tested donated blood by EIA for HIV-1 antibodies [23]. This relatively low
numberofAIDS cases, within a total of 136,204 cases ofAIDS reported to the Centers
for Disease Control as ofJune 30, 1990, would be increased significantly ifasymptom-
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TABLE 1
Results ofTesting American Red Cross Blood Donors for HIV-1
Antibodiesa
Enzyme Immunoassay Western Blot-
Testing Period Repeat Reactive (%) Positive (%)
12-Month Average 0.038 0.011
(10/1/88-9/30/89)
(n = 6,269,300)
Most Current Results 0.029 0.008
(9/1/89-9/30/89)
(n = 510,800)
aResults from 55/56 American Red Cross regions reporting test
results
atic HIV-1-infected transfusion recipients, such as those detected in lookback studies,
were listed also. Answers to the questions ofhow often prolonged seronegative latency
periods occur and whether blood donated during this period is infective remain
unanswered, and research on these issues remains a priority. Current blood donor
deferral practices are based on the assumption that virtually all healthy persons who
become infected by HIV-1 will develop detectable antibodies within six months.
Statistics
The results of current testing for HIV-1 in American Red Cross blood donors are
summarized in Table 1. During the most recent month for which complete test results
are available (September 1989), 0.008 percent of 510,800 donors had positive tests for
HIV-1 antibodies that were confirmed by Western blot.
A study of over 17 million American Red Cross blood donors revealed that the
relative risk (rr) of HIV-1 infection continues to be lowest in repeat female donors
(rr = 1), compared to first-time female donors (rr = 2.4), repeat male donors
(rr = 3.4), and first-time male donors (rr = 9.1) [24]. From the results ofthis study,
and others, it is estimated that the risk of a transfusion recipient contracting HIV
infection is approximately 1:150,000 per unit transfused, or 1:28,000 for a recipient of
the average transfusion (5.4 units) [24].
HIVAntigen
In November 1989, the Food and Drug Administration issued a license for a
diagnostic test kit for HIV-1 p24 antigen (HIV-Ag), raising the possibility that
HIV-Ag testing could be added to current tests ofdonated blood to reduce further the
risk of transfusion-transmitted HIV-1 infection. A multi-organizational study to
evaluate HIV-Ag screening of blood donors was conducted in 12 community blood
centers in the United States. More than 500,000 donors were tested, and none tested
positive for HIV-Ag in the absence ofanti-HIV-1 [25].
Also, addressing the HIV-Ag testing issue from a different perspective, investigators
at Harvard University's John F. Kennedy School and the American Red Cross used a
probabilistic model to estimate the probability that HIV-Ag testing would detect an
additional HIV-infective blood component was approximately 1 in 4,860,000 [26].
This figure projects to an estimate that adding HIV-Ag testing would prevent
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approximately four cases of primary transfusion-transmitted HIV infection annually
in the United States, which would represent approximately one case ofAIDS per year.
For these reasons, neither the Food and Drug Administration nor the national blood
services organizations recommend testing ofdonated blood for HIV-Ag.
HIV-2 (HUMAN IMMUNODEFICIENCY VIRUS, TYPE 2)
Epidemiology
HIV-2, the second human retrovirus identified that is capable ofcausing AIDS, has
been detected primarily in West Africa [27]. Although there is some evidence that
HIV-2 is less pathogenic than HIV-1 [28], HIV-2 infection has caused severe
immunodeficiency and AIDS in a substantial proportion of infected persons [29,30].
An increasing number ofcases ofHIV-2 infection in WestAfrican immigrants or their
sexual contacts have been identified in the United States, Central Africa, South
America, Canada, and Europe [31,32]. In the United States, the Centers for Disease
Control and the Food and Drug Administration tested samples form 8,500 random
blood donors and 16,000 individuals at risk for HIV infection. None of the samples
tested positive for HIV-2 antibodies [33]. Using an EIA for HIV-2 antibodies, the
American Red Cross has retested over 20,000 donor sera that tested repeatedly
reactive for HIV-1 antibodies from 1987-1989, and none contained confirmed HIV-2
antibodies [Fang C: personal communication, May 1, 1990].
Serological Cross-Reactivity
There is considerable serological cross-reactivity between HIV-1 and HIV-2 as a
consequence ofthe homology of HIV-1 and HIV-2 in the gag(77.5 percent),pol (67.5
percent), and env (45.0 percent) regions [34]. Thus, it is not unexpected that
FDA-licensed EIAs for HIV-1 antibodies detect as many as 42-92 percent ofsera from
persons infected by HIV-2 [35,36]. Attempts have been made to utilize this cross-
reactivity to prepare combination HIV-1/HIV-2 enzyme immunoassays. One method
has used an immunoassay employing an epitope of the transmembrane glycoprotein
that is common to both HIV-1 and HIV-2 [37]. Another method has tried to usewhole
virus lysates from both retroviruses in one EIA [38]. In addition, the differences
between HIV-1 and HIV-2 have been utilized to distinguish HIV-1 and HIV-2 by
serological methods [39].
HUMAN T-LYMPHOTROPIC (LEUKEMIA) VIRUS, TYPE I,
AND TYPE II (HTLV-I AND HTLV-II)
Several factors led to the decision to test all donated blood for HTLV-I infection,
even before a case of transfusion-transmitted HTLV-I-related disease had been
reported in the United States and before the FDA-licensed test kits were available
[40,41]. Probably the most important factor in the decision to test donated blood for
HTLV-I infectivity was evidence that persons infected by HTLV-I were donating
blood in the United States, and, as a result, an estimated 2,800 transfusion recipients
would be infected by HTLV-I annually [42].
Statistics
The results of current tests for HTLV-I antibodies in American Red Cross blood
donors are summarized in Table 2. During the most recent month for which complete
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TABLE 2
Results ofTesting American Red Cross Blood Donors for
HTLV-1 Antibodies'
Enzyme Immunoassay Confirmed
Testing Period Repeat Reactive (%) Positive (%)b
6-Month Average 0.070 0.010
(4/1/89-9/30/89)
(n = 2,869,400)
Most Current Results 0.083 0.009
(9/1/89-9/30/89)
(n = 467,400)
aData from 51/56 American Red Cross regions reporting test results
bWestern blot and/or radioimmunoprecipitation assay
test results are available, 0.009 percent of 467,400 donors had positive tests for
HTLV-I antibodies confirmed by Western blot and/or radioimmunoprecipitation
assay.
Donor Risk Factors
As part of the effort to identify risk factors associated with retroviral infections in
potential blood donors, the American Red Cross conducted interviews with donors
whose blood was tested and found tocontain HTLV-I antibodies. A preliminary report
of these findings was presented at the 1989 Annual Meeting of the American
Association of Blood Banks [43]. These data have been updated for inclusion in this
review. As of Februaruy 1, 1990, 482 American Red Cross blood donors with Western
blot or radioimmunoprecipitation assay-confirmed HTLV-I/TI infections have been
interviewed for additional information concerning risk factors for HTLV-I/II. For
these donors, the hierarchical risk ofinfection was greatest for sex with an intravenous
drug user (21.2 percent), followed by birth/sexual contact in the Caribbean (18.9
percent), history of blood transfusion (11.3 percent), intravenous drug use (8.3
percent), birth/sexual contact in Japan (8.1 percent), history of sexually transmitted
disease (6.4 percent), and birth/sexual contact in Africa (1.0 percent). No overt risk
factor was identified for 24.7 percent ofthe persons interviewed.
HTLV-II
Studies of blood donors in American Red Cross regional blood centers, who tested
repeatedly reactive by FDA-licensed HTLV-T enzyme immunoassays, reveal that a
significant number are, in fact, infected by HTLV-II. As of February 1, 1990, genome
amplification studies in 135 Red Cross donors who tested repeatedly reactive by
Abbott Laboratories HTLV-I EIA revealed that the infective agents were HTLV-IT in
49.1 percent; HTLV-I in 48.3 percent; and HTLV-I and -II in 2.6 percent. There were
14.7 percent with negative or unresolved test results [Williams A, et al: unpublished
data]. Thesefindings areconsistent with evidence that HTLV-IT isspreading rapidly in
certain cities in the United States among intravenous drug users [44] and prostitutes
[45]. As a consequence of these observations, reactive HTLV-I EIA results may be
reported as "repeatedly reactive for HTLV-I/II antibodies" meaning HTLV-I and/or
HTLV-IT, pending additional testing to distinguish between HTLV-I and HTLV-II.
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Synthetic HTLVPeptides
To date, distinction of HTLV-I and HTLV-II infection has required viral culture or
a modified polymerase chain reaction (PCR) [46], but these methods are costly,
time-consuming, and limited to a very few research laboratories. As an alternative,
synthetic peptides may be used to distinguish HTLV-I and HTLV-II antibodies. In
one study, synthetic peptides correctly identified 91.7 percent of samples with anti-
HTLV-I and 100.0 percent with anti-HTLV-IT that had been confirmed by PCR [47].
Based on these findings, the American Red Cross's National Reference Laboratory for
Infectious Diseases has begun to use HTLV-I and HTLV-II synthetic peptides as a
part of confirmatory testing, reserving PCR for samples that cannot be characterized
unequivocally by HTLV-I and -II peptide enzyme immunoassays.
CONCLUSION
The data summarized in this review document the significant progress that has been
achieved in recent years to reduce the risk of transfusion-transmitted retroviral
infections.
The number ofblood donors who were subsequently identified by laboratory tests to
be HIV-1 carriers decreased morethan fourfold, from 35 per 100,000donors in 1985 to
eight per 100,000 donors in 1990. For HIV-2, surveillance studies, specific geographic
exclusion criteria for potential donors, and laboratory testing with cross-reacting
HIV-1 reagents are currently in place. Also, national blood collection agencies have
indicated their intention to implement anti-HIV-2 testing, if ongoing surveillance
studies indicate that such testing would be appropriate. For HTLV-I, the results of
nationwide testing of all donated blood for HTLV-I antibodies has yielded two
important observations. First, nearly 50 percent of blood donors with confirmed
positive results by test reagents for HTLV-I antibodies are infected by HTLV-II.
Second, nearly all ofthe HTLV-II-infected persons admit to intravenous drug abuse at
some time, confirming the impression that past intravenous drug use is a major risk
factor for transfusion-transmitted retroviral diseases.
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